Intelligent Bio Solutions Receives NATA Accreditation for its Revolutionary Fingerprint Sweat Drug Screening System
December 19 2023 - 8:30AM
Intelligent Bio Solutions Inc. (“INBS” or the “Company”)
(Nasdaq: INBS), a medical technology company delivering
intelligent, rapid, non-invasive testing solutions, today announced
that it has received National Association of Testing Authorities
(NATA) accreditation for its Intelligent Fingerprinting Drug
Screening Solution.
NATA accreditation is acknowledged nationally
and internationally, and provides a means of recognizing,
determining, and promoting the capability of organizations engaged
in specific technical and scientific activities. NATA's
accreditation follows a rigorous process that meets ISO
Standards, and applications for
accreditation are reviewed by an expert panel, the
Accreditation Advisory Committee (AAC), before an organization
is awarded its accreditation. Aligning with relevant
international standards and addressing compliance, quality and risk
elements, NATA accreditation supports the Company’s business
operations and market presence. The globally recognized
accreditation presents broad opportunities to INBS, which can
provide an alternative drug screening solution to large
corporations with stringent drug and alcohol testing policies.
Harry Simeonidis, President and CEO of
Intelligent Bio Solutions, said, “Receiving NATA accreditation is a
huge accomplishment for the Company and is the result of the
determination and dedication of the team. This opens doors for us
nationally and internationally and underscores our commitment to
upholding the highest standards in the development and delivery of
our Intelligent Fingerprinting Drug Screening System.”
The accreditation serves as an independent
benchmark for technical validation, demonstrating the Company's
commitment to product quality, safety, and reliability for its
customers. This achievement positions INBS as a trusted and
reliable partner, catering to the evolving compliance and safety
needs of organizations across Asia-Pacific and beyond.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is
a medical technology company delivering innovative, rapid,
non-invasive testing solutions. The Company believes that its
Intelligent Fingerprinting Drug Screening System will revolutionize
portable testing through fingerprint sweat analysis, which has the
potential for broader applications in additional fields. Designed
as a hygienic and cost-effective system, the test screens for
recent use of drugs commonly found in the workplace, including
opiates, cocaine, methamphetamine, and cannabis. With sample
collection in seconds and results in under ten minutes, this
technology would be a valuable tool for employers in
safety-critical industries. Additionally, the Company's biosensor
platform has the potential to test for up to 130 indications,
ranging from glucose to immunological conditions and communicable
diseases. The Company's current customer segments include
construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and coroners.
For more information, visit:
https://ibs.inc/
Forward-Looking Statements:
Some of the statements in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934, and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.'s ability to successfully develop and commercialize
its drug and diagnostic tests, realize commercial benefit from its
partnerships and collaborations, and secure regulatory approvals.
Although Intelligent Bio Solutions Inc. believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions Inc. has
attempted to identify forward-looking statements by terminology,
including" believes,"" estimates,"" anticipates,"" expects,""
plans,"" projects,"" intends,"" potential,"" may,"" could,""
might,"" will,"" should,"" approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, included in Intelligent Bio Solutions' public filings
filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company
Contact: Intelligent Bio Solutions
Inc. info@ibs.inc LinkedIn | Twitter
Media Contact: Cheryl
Billson Comma
Communications cheryl.billson@commacomms.com
Intelligent Bio Solutions (NASDAQ:INBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intelligent Bio Solutions (NASDAQ:INBS)
Historical Stock Chart
From Sep 2023 to Sep 2024